Aflac Incorporated reported second-quarter 2025 total revenues of $4.2 billion, a 19.0% decrease from $5.1 billion in the prior year, primarily due to $421 million in net investment losses. The company posted net earnings of $599 million, or $1.11 per diluted share, a significant drop from $1.8 billion, or $3.10 per diluted share, in Q2 2024.
Despite the decline in GAAP net earnings, adjusted earnings for the quarter were $957 million, a 7.5% decrease from Q2 2024, but adjusted earnings per diluted share of $1.78 beat Wall Street estimates. Aflac Japan's new annualized premium sales increased significantly by 23.2% to ¥20.7 billion, driven by strong sales of the new Miraito cancer insurance product.
Aflac U.S. net earned premiums increased 3.4% to $1.5 billion, and sales grew 2.7% to $340 million, primarily from group life and disability products. The company deployed $829 million in capital to repurchase 7.9 million of its common shares during the quarter and declared a third-quarter dividend of $0.58 per share.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.